Clinical Pearl from Dr. @JKolfenbach ⭐️AAV doesn't typically cause hard palate lesions Instead, consider: ➡️Cocaine-induced midline destructive lesion ➤try to send human neutrophil elastase ab (+ in cocaine use but not in AAV) ➡️Malignancy (NK T-cell lymphoma) #ACR21 @RheumNow https://t.co/KIEXgCR23c

TNFi vs tofacitinib drug survival in RA (based on two Canadian registries, PS adjusted) This seems to be my refrain this ACR: 'TNF inhibitors: let's not forget, they're quite good' #ACR21 ABST1217 @RheumNow @Janetbirdope https://t.co/MyFc6do0JL

Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq

FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc

FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m

FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le

FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej

FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH

FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW

#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC: ⬇️Titres of Abs in SLE vs controls 💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA 📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9

Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5

"Managing comorbidities can really improve outcomes for our patients" @UnaMakris highlights the bio-psycho-social approach to multicomplexity and multimorbidity in our older patients with RA. #ACR21 @RheumNow https://t.co/TMLqoreogZ